Access ESMO scientific and educational resources on Lymphomas
Recent medwireNews and resources from conferences are for ESMO Members only.
Lymphomas
Lymphomas
Clinical Practice Guidelines
Latest ESMO videos
Featured medwireNews
CAR T-Cell Therapy Achieves Relapsed/Refractory Indolent NHL Response
Cardiac Monitoring Need Highlighted For Non-Hodgkin’s Lymphoma Patients
2-Year ZUMA-1 Results Add Support For Axicabtagene Ciloleucel In Refractory Large B-Cell Lymphoma
High Response Rates With Tisagenlecleucel In Adult Refractory DLBCL Patients
Ibrutinib–Rituximab Improves Waldenström’s Macroglobulinemia PFS
E-Learning
ESMO E-Learning: Open Questions in the Treatment of Follicular Lymphoma
ESMO E-Learning: Mantle Cell Lymphoma
ESMO E-Learning: Modern Management of DLBCL
ESMO E-Learning: The Lugano Classification recommendations for Hodgkin’s and non-Hodgkin’s lymphoma: Staging, Response Assessment and Follow Up
ESMO E-Learning: DLBCL Clinical case - Adherence to the ESMO Clinical Practice Guidelines
Meeting resources
20P - IGN002 (antiCD20-IFNα2b) intravenously administered tumour targeted delivery of IFNα2b and its effects in non-Hodgkin lymphoma
Presenter: Sribalaji Lakshmikanthan
Session: ePoster Display Session
Resources:
Abstract
33MO - A phase I study of SHC014748M capsules in patients with relapsed or refractory indolent B-cell malignancies
Presenter: Wei Xu
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
83P - Development of steroid-refractory graft-versus-host disease in a patient with Hodgkin lymphoma treated with nivolumab before allogeneic hematopoietic stem cells transplantation
Presenter: Beynarovich Anastasiya
Session: e-Poster Display Session
Resources:
Abstract
49P - Discontinuation of immune checkpoint inhibitors in patients with relapsed and refractory classical Hodgkin lymphoma
Presenter: Liudmila Fedorova
Session: e-Poster Display Session
Resources:
Abstract
29P - ALLELE study: A multicenter, open label, phase III study of tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after failure of rituxima
Presenter: Nina Worel
Session: e-Poster Display Session
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.